2QK Stock Chart & Stats
€49.24
€1.40(3.34%)
At close: 4:00 PM EDT
€49.24
€1.40(3.34%)
Day’s Range― - ―
52-Week Range€23.60 - €53.00
Previous CloseN/A
Volume80.00
Average Volume (3M)28.00
Market Cap
€4.37B
Enterprise Value€6.90B
Total Cash (Recent Filing)€492.09M
Total Debt (Recent Filing)€203.83M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 10, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding121,785,280
10 Day Avg. Volume3
30 Day Avg. Volume28
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€62.10Price Target Upside26.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.97
Revenue Forecast (FY)€4.99M
Bulls Say, Bears Say
Bulls Say
FDA Approval Enables Commercial LaunchFDA approval converts apitegromab from a development program into a commercial product and supports immediate U.S. launch activity. This creates a potential recurring revenue base, strengthens Scholar Rock’s position in neuromuscular disease, and provides a foundation for broader physician and payer adoption.
Clinically Meaningful Efficacy In SMAThe pivotal efficacy result provides a durable clinical rationale for using ISEMBYLD alongside SMN2-targeted therapy. Demonstrated motor-function improvement can support physician confidence, payer discussions, and patient uptake while differentiating the product within the SMA treatment landscape.
Substantial Liquidity And Financing FlexibilityA sizable cash balance and additional financing levers give Scholar Rock resources to support commercialization, regulatory obligations, and pipeline development. This liquidity should reduce immediate funding pressure and provide flexibility while the company works to establish product revenue and manage launch costs.
Bears Say
Heavy Cash Burn And Widening LossesScholar Rock remains dependent on external funding because operating and free cash flow are deeply negative while losses continue to widen. Sustained spending on research and commercialization could consume liquidity, increase financing needs, and limit the company’s flexibility if product revenue ramps slowly.
Post-marketing Safety Obligations And Fracture MonitoringThe required pregnancy study and accelerated fracture reporting create ongoing regulatory, operational, and reputational obligations after approval. The safety-monitoring burden may increase costs and could affect physician or payer confidence if additional fracture-related findings emerge during broader real-world use.
Payer Access May Slow Early AdoptionPrior-authorization requirements and expected early reimbursement friction could delay treatment starts even after FDA approval. Longer prescription-to-infusion cycles may slow revenue conversion, increase support costs, and make the commercial ramp less predictable during the product’s first months in the market.
Scholar Rock Holding News
2QK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was €23.60 and its highest was €53.00 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is €4.37B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Aug 06, 2026. The company reported -€0.749 earnings per share for the quarter, beating the consensus estimate of -€0.75 by <€0.001.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.75.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 121,785,280 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -€0.749 in its last earnings report, beating expectations of -€0.75. Following the earnings report the stock price went up 1.073%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in DE:2QK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€62.10 (26.12% Upside)
€62.10 (26.12% Upside)
Blogger Sentiment
Bullish
DE:2QK Sentiment 80%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.02%
12-Months-Change
Fundamentals
Return on Equity
-160.19%
Trailing 12-Months
Asset Growth
53.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
2QK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong forward momentum: the BLA is accepted with a fixed PDUFA date, management has established two independent manufacturing paths (reducing single-site risk), commercial operations are launch-ready, the pipeline is advancing (Phase II OPAL recruitment, FORGE initiated, SRK-439 dosing), and the company finished the quarter with a healthy cash balance and financing optionality. Main negatives are the outstanding FDA inspection classification for Catalent Indiana (which also affects EMA timing), ongoing third-party manufacturing/regulatory timing risk, and expected payer/reimbursement friction that could delay patient access after approval. On balance, the positive regulatory progress, commercial preparedness, clinical achievements and solid cash position outweigh the operational and reimbursement risks discussed on the call.View all DE:2QK earnings summaries2QK Stock 12 Month Forecast
Average Price Target
€62.10
▲(26.12% Upside)
Technical Analysis
Cytokinetics
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Dyne Therapeutics
―
Edgewise Therapeutics
―